Browse the evidence

Impulsiveness (measured by BIS-11 and MCQ) and temporal discounting (preference for immediate rewards) are significant predictors of weight regain, as they correlate with higher caloric intake and poor adherence to dietary restrictions.

If you find it hard to stick to your diet, it might not just be a lack of discipline. Your brain's tendency to prefer immediate rewards (like tasty food) over long-term goals (like health) plays a role. Recognizing this 'impulsiveness' can help you implement strategies to manage it, such as removing triggers or planning ahead.

Metabolic adaptation (energy expenditure below expected levels) and appetite adaptation (increased energy intake) are coregulated and inseparable factors in weight regain.

Don't try to fix weight maintenance by only focusing on diet or only on exercise. Your body's hunger signals and energy burn are linked. Effective long-term strategies need to address both sides of the energy balance equation simultaneously.

Maintaining weight loss induced by anti-obesity drugs may require lifelong use unless effective adjunct strategies for weight maintenance are available.

If you use medication for weight loss, understand that it may need to be long-term. This is similar to managing other chronic conditions. The goal of research like POWERS is to find adjunct strategies that might reduce this dependency.

Semaglutide treatment in patients with chronic ankle instability (CAI) significantly improves patient-reported functional outcomes (FAAM, FAOS, CAIT) and reduces the incidence of recurrent ankle sprains and surgery, with approximately one-third of the benefit mediated by weight loss.

For patients with chronic ankle instability, especially those who are overweight or have type 2 diabetes, semaglutide may offer benefits beyond metabolic control. It is associated with improved ankle function, fewer sprains, and lower surgery rates. While weight loss contributes to this, it is not the only factor. Patients should discuss this potential orthopedic benefit with their prescribing physician, particularly if they are considering surgical intervention for ankle instability.

Higher body mass index (BMI) is associated with lower self-reported physical functioning and overall health-related quality of life (HRQoL) in people with overweight or obesity.

If you have overweight or obesity, you are statistically more likely to experience reduced physical functioning and lower quality of life as your BMI increases. This is not just about appearance; it affects your daily physical capacity and general health perception. Addressing weight and associated comorbidities is a key lever for improving these functional outcomes.

The presence of cardiovascular (CV) or metabolic comorbidities significantly reduces health-related quality of life (HRQoL) and work productivity in people with overweight or obesity, independent of BMI alone.

Having overweight or obesity is not the only factor affecting your health and work. If you have cardiovascular or metabolic conditions (like diabetes or high blood pressure), these significantly impact your quality of life and productivity. Treating these comorbidities alongside weight management is crucial for improving your daily well-being.

People with overweight or obesity experience significant work productivity impairment, particularly in terms of presenteeism and activity impairment, when they have metabolic comorbidities.

If you have overweight or obesity and metabolic conditions like diabetes, you may experience reduced work effectiveness (presenteeism) and activity limitation. This is a measurable impact of your health conditions. Managing these conditions can help improve your work productivity and overall well-being.

Semaglutide use for rapid weight loss causes 'semaglutide face,' characterized by facial hollowing, skin sagging, and premature aging due to subcutaneous fat loss, collagen depletion, and muscle mass reduction.

If you are using semaglutide for weight loss, be aware that rapid fat and muscle loss can cause your face to look hollow or sagged. This is a known side effect called 'semaglutide face.' You can discuss preventative or corrective measures like dermal fillers, PRP, or radiofrequency microneedling with your provider to maintain your appearance while losing weight.

Lifestyle modifications (diet, exercise, behavioral therapy) are foundational but have limited efficacy for severe obesity when used alone.

Lifestyle changes (diet, exercise, counseling) are the foundation of obesity treatment. However, for severe obesity (BMI ≥35), they are often not enough on their own. Combine them with medical or surgical options for best results.

GLP-1 receptor agonists (GLP-1RAs) are perceived by primary care providers as effective and promising tools for managing recurrent weight gain after metabolic bariatric surgery (MBS), offering renewed optimism and life-changing results for patients.

If you have had bariatric surgery and are regaining weight, GLP-1 medications like semaglutide are a viable and effective option to help you lose weight again. However, they are not a magic bullet; you must continue to focus on diet and exercise. The main barrier is cost, so work with your provider to navigate insurance coverage or assistance programs.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) significantly suppress hunger, reduce 'food noise' (intrusive thoughts about food), and increase early satiety during the dynamic weight loss phase, leading to reduced portion sizes and cravings.

When starting GLP-1 medications, expect a significant reduction in hunger and intrusive thoughts about food ('food noise'). This is a biological effect, not just willpower. You may feel full faster and eat smaller portions. This effect is strongest in the first few months (dynamic phase). If you stop the medication, hunger and food noise typically return, so long-term adherence is often necessary for sustained benefits.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), significantly improves psoriasis symptoms and quality of life, with effects potentially linked to increased GLP-1 levels post-surgery.

If you have severe obesity and psoriasis, and lifestyle changes plus medications haven't worked, bariatric surgery (especially gastric bypass) can be a powerful option. It not only helps with weight but can significantly improve your psoriasis symptoms, likely by boosting your body's natural GLP-1 levels. This is a major step, so it's reserved for those with higher BMI or uncontrolled comorbidities.

Lifestyle interventions, specifically the Mediterranean diet and moderate-to-vigorous exercise, improve psoriasis symptoms and quality of life, independent of weight loss.

Start with lifestyle changes. Adopt a Mediterranean diet, which has anti-inflammatory properties that can help your psoriasis regardless of weight loss. Aim for 150 minutes of moderate exercise per week, plus strength training. If sweating bothers your skin, try swimming or other low-impact activities. Be patient and gradual to avoid discouragement.

Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.

If you are struggling with current GLP-1 therapies or need more aggressive weight loss, triple-agonist medications like retatrutide are the next step. They work by hitting three metabolic targets at once, leading to much higher weight loss (up to 24%) than standard drugs. This is currently an injectable treatment, but oral alternatives are being developed.

Oral GLP-1 receptor agonists (e.g., orforglipron) provide comparable efficacy to injectable formulations while improving accessibility by eliminating cold-chain requirements.

If you prefer pills over injections, oral GLP-1 medications like orforglipron are a viable option. They work similarly to shots but are taken daily by mouth, which may help you stick with the treatment longer. They are also easier to store and distribute globally.

Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.

If you are not getting enough weight loss or side effects from GLP-1s alone, adding an amylin analog (like cagrilintide) to your regimen might help. This combination works through a different mechanism in your brain and gut, leading to significant weight loss (around 20%) and potentially better tolerability.

Body composition-targeted agents (e.g., bimagrumab) preserve or increase lean mass while reducing fat mass, addressing the functional decline associated with rapid weight loss.

If you are concerned about losing muscle while losing weight, ask your doctor about body composition-targeted therapies. Drugs like bimagrumab are designed to burn fat while building or preserving muscle, which helps maintain strength and function.

Testosterone Replacement Therapy (TRT) increases lean body mass and improves body composition in men with documented low testosterone, but no trials have evaluated its combined use with GLP-1 RAs.

If you are a man with low testosterone, TRT can help preserve muscle. However, doctors should check your levels before starting, and there is no proof yet that taking TRT alongside GLP-1s prevents muscle loss better than TRT alone.

The Russian semaglutide-based drug Velgia® (WRYC12301) demonstrates bioequivalence, high safety, and lack of immunogenicity compared to the reference drug Wegovy® at doses of 0.25 mg and 2.4 mg.

This study confirms that the Russian semaglutide product Velgia® is bioequivalent to the brand-name Wegovy® at both 0.25 mg and 2.4 mg doses. It has a comparable safety profile with mild side effects and no detected immunogenicity (antibody formation). For patients seeking this treatment, this generic option offers the same pharmacokinetic exposure as the reference drug.

Subsidized participation in commercial weight management programs improves engagement and reduces attrition compared to non-subsidized participation, without compromising weight loss outcomes.

If you cannot afford a commercial weight loss program, look for subsidies from your health insurance or employer. Financial assistance can make these programs more accessible and help you stay engaged without increasing your out-of-pocket costs.

Technology-assisted obesity interventions, including digital platforms and AI-driven adaptive interventions, can produce clinically meaningful weight loss and improve equity by increasing reach to marginalized populations.

Digital weight loss programs can be effective and affordable. If you have a smartphone, you may have access to these programs. Look for options that offer human support if you need extra motivation, as combining technology with coaching yields better results.

In integrated primary care weight management, achieving clinically meaningful weight loss (≥5% initial body weight) is significantly associated with higher treatment visit frequency and the simultaneous prescription of two or more anti-obesity medications (AOMs).

To maximize your chances of losing at least 5% of your body weight, commit to attending your scheduled monthly appointments for the first six months and discuss with your doctor the potential benefit of using two anti-obesity medications simultaneously if one isn't working. Consistent engagement and combination therapy were key factors in successful weight loss trajectories in this study.

A history of metabolic surgery (specifically sleeve gastrectomy) significantly attenuates the weight-loss efficacy of liraglutide in patients with mild obesity, resulting in substantially lower total weight loss compared to non-surgical patients.

If you have had weight-loss surgery (especially sleeve gastrectomy), standard doses of liraglutide may not work as well as they do for others. Your doctor might need to increase your dose to 3.0 mg (if approved/available) or switch you to a different medication like tirzepatide to achieve similar weight loss results. Do not assume the standard dose will be sufficient.

Systematic screening for heart failure with preserved ejection fraction (HFpEF) in asymptomatic or mildly symptomatic individuals with obesity is clinically indicated to enable early detection and intervention, as obesity-related HFpEF presents with distinct pathophysiology and earlier onset.

If you have obesity, do not assume shortness of breath or fatigue is 'just part of being overweight.' Ask your doctor about screening for heart failure with preserved ejection fraction (HFpEF), especially if you have other risk factors like high blood pressure or atrial fibrillation. Early detection through specific tests (like echocardiograms or biomarker adjustments) can allow for treatments that prevent heart failure from developing.